Menu
Fechar
hrs4r
 I want to donate

PILAR BARRETINA GINESTA

Precision Oncology in Girona
Firma
PILAR BARRETINA-GINESTA
Position
Investigador/a Pre-doctoral – R1
Predoctoral Researchers – R1
Publicacions

Publicacions

Tavira B, Iscar T, Manso L, Santaballa A, Gil-Martin M, García García Y, Romeo M, Iglesias M, de Juan Ferré A, Barretina-Ginesta MP, Manzano A, Gaba L, Rubio MJ, de Andrea CE, González-Martín A

Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

CLINICAL CANCER RESEARCH, 2024, 30, 176-186 dx.doi.org/10.1158/1078-0432.CCR-23-0771
Bogani G, Monk BJ, Powell MA, Westin SN, Slomovitz B, Moore KN, Eskander RN, Raspagliesi F, Barretina-Ginesta MP, Colombo N, Mirza MR

Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer

ANNALS OF ONCOLOGY, 2024, 35, 414-428 dx.doi.org/10.1016/j.annonc.2024.02.006
Vulsteke, C, Chambers, SK, Pérez, MJR, Chan, JK, Raaschou-Jensen, N, Zhuo, Y, Lorusso, D, Herzog, TJ, Rouge, TD, Pepin, JAT, Braicu, EI, Chen, LM, Levy, T, Barter, JF, Barretina-Ginesta, MP, Joosens, E, York, W, Malinowska, IA, González-Martín, A, Monk, BJ

Tolerability of the niraparib individualized starting dose in the PRIMA/ ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

EUROPEAN JOURNAL OF CANCER, 2024, 208, 114157-114157 dx.doi.org/10.1016/j.ejca.2024.114157
Leary A, Estévez-García P, Sabatier R, Ray-Coquard I, Romeo M, Barretina-Ginesta P, Gil-Martin M, Garralda E, Bosch-Barrera J, Morán T, Martin-Martorell P, Nadal E, Gascón P, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfon J, Domenech C, Pérez-Fidalgo A, Oaknin A

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.

Bmc Cancer, 2024, 24, 911-911 dx.doi.org/10.1186/s12885-024-12700-0
Leary A, Estévez-García P, Sabatier R, Ray-Coquard I, Romeo M, Barretina-Ginesta P, Gil-Martin M, Garralda E, Bosch-Barrera J, Morán T, Martin-Martorell P, Nadal E, Gascón P, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfon J, Domenech C, Pérez-Fidalgo A, Oaknin A

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.

Bmc Cancer, 2024, 24, 876-876 dx.doi.org/10.1186/s12885-024-12501-5
Hernandez, MM, Costa, SC, Coloma, CS, Cutillas, AQ, Barretina-Ginesta, MP, Sanchís, AC

First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature

CLINICAL & TRANSLATIONAL ONCOLOGY, 2024 dx.doi.org/10.1007/s12094-024-03609-y
Perez-Fidalgo, JA, Gálvez-Montosa, F, Guerra, EM, Madariaga, A, Manzano, A, Martin-Lorente, C, Rubio-Pérez, MJ, Alarcón, J, Barretina-Ginesta, MP, Gaba, L

SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023)

CLINICAL & TRANSLATIONAL ONCOLOGY, 2024 dx.doi.org/10.1007/s12094-024-03531-3
Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Fariñas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesta MP

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.

LANCET ONCOLOGY, 2024, 25, 1135-1146 dx.doi.org/10.1016/S1470-2045(24)00334-6
Redondo A, Barretina P, Pérez-Fidalgo A, Rubio MJ, González-Martín A

Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus

JOURNAL OF GYNECOLOGIC ONCOLOGY, 2023, 34 dx.doi.org/10.3802/jgo.2023.34.e57
Fernández-Serra A, López-Reig R, Márquez R, Gallego A, de Sande LM, Yubero A, Pérez-Segura C, Ramchandani-Vaswani A, Barretina-Ginesta MP, Mendizábal E, Esteban C, Gálvez F, Sánchez-Heras AB, Guerra-Alía EM, Gaba L, Quindós M, Palacio I, Alarcón J, Oaknin A, Aliaga J, Ramírez-Calvo M, García-Casado Z, Romero I, López-Guerrero JA

The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer-A GEICO Study

Cancers, 2023, 15 dx.doi.org/10.3390/cancers15113030

Formulari de contacte

About IDIBGI!

 menu